Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.34 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.33 |
| ▸ | TPSD1 | Q9BZJ3 | 4/20 | 0.33 |
| ▸ | TPSG1 | Q9NRR2 | 4/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4029549 | 1.00 | KLK7 (0.34) | KLK7TPSAB1TPSD1TPSG1FAAH | |
| SCHEMBL4029547 | 1.00 | KLK7 (0.34) | KLK7TPSAB1TPSD1TPSG1FAAH | |
| SCHEMBL4177476 | 0.84 | KLK7 (0.33) | KLK7TPSAB1TPSD1TPSG1FAAH | |
| SCHEMBL5756476 | 0.82 | KLK7 (0.34) | KLK7TPSAB1TPSD1TPSG1FAAH | |
| SCHEMBL5756469 | 0.82 | KLK7 (0.34) | KLK7TPSAB1TPSD1TPSG1FAAH | |
| SCHEMBL5756481 | 0.82 | KLK7 (0.34) | KLK7TPSAB1TPSD1TPSG1FAAH | |
| SCHEMBL7229836 | 0.81 | KLK7 (0.32) | KLK7TPSAB1TPSD1TPSG1 | |
| SCHEMBL6601963 | 0.81 | TPSAB1 (0.37) | TPSAB1TPSD1TPSG1NR1H2 | |
| SCHEMBL5756685 | 0.81 | KLK7 (0.32) | KLK7TPSAB1TPSD1TPSG1 | |
| SCHEMBL6601957 | 0.81 | TPSAB1 (0.37) | TPSAB1TPSD1TPSG1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372636-B1 | METRONOMIC DOSING OF TAXANES FOR INHIBITING TUMOR GROWTH | BRISTOL MYERS SQUIBB CO (US) | 2006-06-28 | — | — | EP | disclosed |
| EP-1146043-B1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | UNIV FLORIDA STATE (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1623706-A2 | Metronomic dosing of taxanes for inhibiting tumor growth | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-08 | — | — | EP | disclosed |
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| US-20040143004-A1 | Metronomic dosing of taxanes | CERAM TEC AG, INNOVATIVE CERAMIC ENGINEERING (DE) | 2004-07-22 | — | — | US | disclosed |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | FLORIDA STATE UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| EP-0667772-B1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV FLORIDA STATE (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| US-6537988-B2 | Imidazole-1h-1,4-benzodiazepine derivatives along with antiproliferative cytotoxic and cytostatic agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-25 | — | — | US | disclosed |
| EP-1251846-A4 | C-4 CARBONATE TAXANES | BRISTOL MYERS SQUIBB CO (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6521660-B2 | Anticancer, antitumor agents | FLORIDA STATE UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| EP-1272193-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Bristol-Myers Squibb Company (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1251846-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY | 2002-10-10 | — | — | US | disclosed |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-03 | — | — | US | disclosed |
| US-6335362-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR LEUKEMIA | FLORIDA STATE UNIVERSITY | 2002-01-01 | — | — | US | disclosed |
| EP-1146043-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001072721-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001056565-A1 | C-4 CARBONATE TAXANES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143004-A1 | Metronomic dosing of taxanes | MTDH, MCL1, CCNA1 | KLK7 1612/4885TPSAB1 2925/4885TPSD1 3144/4885 |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | KLK7 4239/4885TPSAB1 3848/4885TPSD1 3390/4885 |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | MCL1, TP53, EWSR1 | KLK7 4778/4885TPSAB1 3330/4885TPSD1 3146/4885 |
| US-20020002162-A1 | Synergistic methods and compositions for treating cancer | ABCB11, TP53, SLC10A1 | KLK7 710/4885TPSAB1 1642/4885TPSD1 2715/4885 |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | TOP2A, TOP2B, TUBB3 | KLK7 2160/4885TPSAB1 2941/4885TPSD1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.